Lasting Legacy of COVID-19 on Clinical Trial Design and Management
Jul 26, 2024 Abstract COVID-19 appears to have been the catalyst required to overcome prior reluctance to embrace decentralized trials. In March, the FDA issued guidance recommending the use of virtual visits and virtual assessments in ongoing trials whenever feasible [1]. It also allowed for these changes to be implemented immediately, prior to formal IRB […]
GLP1, SGLT2 and AI in Longevity: Where the Real Value Lies
Background: Biology Meets Commercial Reality Santulli et al. (2024) present a compelling scientific hypothesis: that GLP1 receptor agonists and SGLT2 inhibitors, originally developed for type 2 diabetes, may exert systemic effects relevant to human longevity. These include reductions in cardiovascular and renal risk, anti-inflammatory properties, and potential neuroprotective effects. Concurrently, artificial intelligence is transforming how we […]